|
Balance Sheet Cash Flow Statement 100 Saw Mill Rd. Danbury, CT 06810 CT Tel. 203-796-5000 Fax 203-796-5001 |
Type: Public
On the web:
http://www.biodel.com
Employees:
60
Employee growth: 100.0%
Biodel delves into the development of viable treatments for endocrine disorders. The company uses its VIAdel biological technology to reformulate and administer existing peptide drugs. Its two main product candidates are in clinical trials for treating diabetes. Biodel's VIAject insulin formula is designed to be rapidly absorbed into the bloodstream following injection, while its VIAtab insulin tablets are administered orally. Two additional products aimed at treating osteoporosis, VIAmass and VIAcal, are in preclinical development. Members of Biodel's board of directors together own more than 50% of the company; prior to its 2007 IPO, they controlled over 80%.
Key numbers for fiscal year ending September, 2009:
Sales: $0.0M
Net income: ($43.3)M
Officers:
Chairman, President, and CEO: Solomon S. Steiner
VP Operations: Erik Steiner
VP Corporate Development, CFO, and Treasurer: Gerard J. (Gerry) Michel
Competitors:
Eli Lilly
Novo Nordisk
Sanofi-Aventis
